Table 2.
Comparison between CD4+ and CD8+ T lymphocyte numbers and CD4/CD8 ratio improvement in the 24 months following the start of cART in the following two AIDS-presenting patient subgroups: HBcAb-positive and HBcAb-negative.
| AIDS patients/HBcAb- (n = 20) | AIDS patients/HBcAb+ (n = 28) | p value | |
|---|---|---|---|
| Median (IQR) CD4 count, 1st month | 96 (14.5–130.5) | 143 (53–265) | 0.12 |
| Median (IQR) CD4 count, 2nd month | 89.5 (62.0–275.5) | 202.5 (104.5–305.0) | 0.15 |
| Median (IQR) CD4 count, 3rd month | 137.5 (91.5–193.0) | 212 (137.5–361.0) | 0.08 |
| Median (IQR) CD4 count, 4th month | 134.5 (105.5–257.0) | 211 (158–360) | 0.09 |
| Median (IQR) CD4 count, 5th month | 172 (135.0–259.5) | 254 (139–410) | 0.09 |
| Median (IQR) CD4 count, 6th month | 165 (118.5–262.0) | 323 (118–408) | 0.18 |
| Median (IQR) CD4 count, 12th month | 237 (146.0–296.5) | 321.5 (160–465) | 0.21 |
| Median (IQR) CD4 count, 24th month | 343 (227–521) | 476 (272–551) | 0.17 |
| Median (IQR) CD8 count, 1st month | 350 (233.5–533.0) | 556 (273–811) | 0.13 |
| Median (IQR) CD8 count, 2nd month | 426 (258–671) | 661.5 (393–1094) | 0.03 |
| Median (IQR) CD8 count, 3rd month | 430.5 (328.5–699.0) | 726.5 (538–1291) | 0.01 |
| Median (IQR) CD8 count, 4th month | 523.5 (356.5–757.0) | 857 (562–1434) | 0.006 |
| Median (IQR) CD8 count, 5th month | 493 (359.5–741.5) | 825 (636–1327) | 0.008 |
| Median (IQR) CD8 count, 6th month | 466.5 (368.5–765.0) | 822 (598–1180) | 0.007 |
| Median (IQR) CD8 count, 12th month | 559.5 (382.0–899.5) | 831.5 (621–1079) | 0.01 |
| Median (IQR) CD8 count, 24th month | 700 (450–990) | 1038 (530–1239) | 0.05 |
| Median (IQR) CD4/CD8 ratio, 1st month | 0.22 (0.08–0.40) | 0.22 (0.07–0.42) | 0.86 |
| Median (IQR) CD4/CD8 ratio, 2nd month | 0.28 (0.14–0.47) | 0.28 (0.13–0.38) | 0.79 |
| Median (IQR) CD4/CD8 ratio, 3rd month | 0.27 (0.14–0.55) | 0.28 (0.10–0.42) | 0.77 |
| Median (IQR) CD4/CD8 ratio, 4th month | 0.33 (0.17–0.50) | 0.29 (0.11–0.39) | 0.25 |
| Median (IQR) CD4/CD8 ratio, 5th month | 0.44 (0.16–0.50) | 0.35 (0.14–0.40) | 0.20 |
| Median (IQR) CD4/CD8 ratio, 6th month | 0.36 (0.18–0.60) | 0.34 (0.12–0.47) | 0.34 |
| Median (IQR) CD4/CD8 ratio, 12th month | 0.43 (0.24–0.60) | 0.36 (0.21–0.52) | 0.40 |
| Median (IQR) CD4/CD8 ratio, 24th month | 0.51 (0.30–0.68) | 0.44 (0.24–0.79) | 0.58 |
| CD4/CD8 ratio < 0.45, 1st month, n (%) | 17 (85.0) | 23 (82.1) | 0.79 |
| CD4/CD8 ratio < 0.45, 2nd month, n (%) | 15 (75.0) | 22 (78.6) | 0.77 |
| CD4/CD8 ratio < 0.45, 3rd month, n (%) | 14 (70.0) | 24 (85.7) | 0.19 |
| CD4/CD8 ratio < 0.45, 4th month, n (%) | 12 (60.0) | 24 (85.7) | 0.04 |
| CD4/CD8 ratio < 0.45, 5th month, n (%) | 12 (60.0) | 23 (82.1) | 0.09 |
| CD4/CD8 ratio < 0.45, 6th month, n (%) | 11 (55.0) | 20.0 (71.4) | 0.24 |
| CD4/CD8 ratio < 0.45, 12th month, n (%) | 10 (50.0) | 18 (64.3) | 0.32 |
| CD4/CD8 ratio < 0.45, 24th month, n (%) | 8 (40.0) | 17 (60.7) | 0.16 |
| CD4/CD8 ratio recovery ≥ 0.45 at 24th month, n (%) | 10 (58.8) | 10 (43.5) | 0.34 |
| Immunological success at 24th month, n (%) | 14 (70.0) | 24 (85.7) | 0.28 |